Suchergebnisse - "Podzamczer, Daniel"

PubPharm (21)

1

Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Imaz, A. | Tiraboschi, J. | Niubó, J. | +14

2

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The lancet. HIV | 2021

von Ogbuagu, O. | Ruane, P. | Podzamczer, D. | +118

ErratumIn: Lancet HIV. 2021 Dec;8(12):e734. - PMID 34571044

3

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

4

Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019

von Imaz, A. | Niubó, J. | Cottrell, M. | +6

5

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate : a pooled analysis of 26 clinical trials

enthalten in: AIDS (London, England) | 2019

von Gupta, S. | Post, F. | Arribas, J. | +21

6

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1 : 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Ward, D. | Brar, I. | +12

CommentIn: Lancet HIV. 2018 Jul;5(7):e336-e337. - PMID 29925488

7

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults : a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

enthalten in: The lancet. HIV | 2018

von Winston, A. | Post, F. | DeJesus, E. | +14

CommentIn: Lancet HIV. 2018 Apr;5(4):e156-e157. - PMID 29475803

8

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients : A Randomized, Multinational, Multicenter Trial

enthalten in: PloS one | 2016

von Cooper, D. | Cordery, D. | Zajdenverg, R. | +87

9

The lipid-lowering effect of tenofovir/emtricitabine : a randomized, crossover, double-blind, placebo-controlled trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2015

von Santos, J. | Saumoy, M. | Curran, A. | +10

10

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection : two randomised, double-blind, phase 3, non-inferiority trials

enthalten in: Lancet (London, England) | 2015

von Sax, P. | Wohl, D. | Yin, M. | +122

CommentIn: Lancet. 2015 Jun 27;385(9987):2559-60. - PMID 25890672